At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Degree of Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Positron Emission Tomography With Amyloid Markers (PET-CT 18F-Florbetaben) and Comparison With MRI Findings
In Brief
A clinical study evaluating 18F-florbetaben PET/CT for Multiple Sclerosis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The goal of this clinical trial study is to evaluate the presence of relationships between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), apparent absence of inflammatory activity (silent plaques without microglial rim), or indicative of more recent inflammatory activity, in contrast-enhanced areas or in T2/Flair-positive areas of not distant onset in patients diagnosed with progressive (secondary or primary) stage multiple sclerosis and in patients in relapse and remission. Laboratory analysis of serum markers will be performed: neuronal and glial cytoskeletal proteins (e.g., Nf-L, pN-FH, GFAP), and the levels of neurotrophic factors (e.g., BDNF, GDNF) and cytokines (e.g., TNFα, IL-6, IL-1β, interferon) will be evaluated.
Study Details
Timeline
Interventions
The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition. Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available. A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline. Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake.